Company Overview
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Why Investors Should Care
Net profit has compounded at 30.3% per year over the last five years.
Revenue has grown at a 64.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $490.73M (+110.5% YoY); net profit $-25.55M.
- Trailing 12 Months Year-on-year growth — revenue +55.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 64.9%, profit CAGR 30.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 64.89% |
| 1 Year: | 55.60% |
Compounded Profit Growth
| 5 Years: | 30.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +237.43% |
| 6 Months: | +65.01% |
| 3 Months: | +85.86% |
| 1 Month: | +16.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 64.9% over 5 years.
- Profit CAGR of 30.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TVTX Travere Therapeutics, Inc. R2K | 57.06 | -114.12 | $5.31B | 0.00% | -8.65% | -69.38% | 64.89% | 30.28% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 33.62M | 38.80M | 40.34M | 42.18M | 38.43M | 41.34M | 40.71M | 43.77M | 39.57M | 44.71M | 44.37M | 46.69M | 47.77M | 48.43M | 51.14M | 50.98M | 47.41M | 54.62M | 68.22M | 23.41M | 28.63M | 28.07M | 29.34M | 30.89M | 32.20M | 37.09M | 45.06M | 41.37M | 54.12M | 62.90M | - | 81.73M | 114.45M | 164.86M | 129.69M | 127.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.10M | 1.52M | 1.58M | 2.55M | 26.77M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.63M | 112.93M | 163.27M | 127.14M | 100.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 107.30M | 125.58M | 138.34M | 159.56M | 137.35M |
| Operating Income | -8.24M | -11.38M | -20.37M | -18.22M | -14.41M | -13.60M | -10.61M | -15.18M | -17.91M | -21.56M | -35.58M | -4.99M | -38.23M | -36.53M | -34.44M | -28.17M | -15.07M | -23.11M | -19.43M | -118.55M | -47.55M | -35.31M | -31.71M | -71.98M | -78.53M | -82.60M | -86.70M | -97.37M | -103.95M | -92.58M | -94.23M | -139.24M | -67.70M | -56.15M | - | -42.67M | -12.65M | 24.93M | -32.43M | -36.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.53M | 4.13M | 44.25M | -632.00K | -9.21M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.86M | 2.85M | 2.75M | 2.30M | 2.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.19M | -12.73M | 25.71M | -21.07M | -36.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00K | 20.00K | 8.00K | 921.00K | -120.00K |
| Net Income | 11.22M | -13.40M | -37.11M | -8.60M | -11.09M | -13.23M | -17.79M | -17.62M | -18.38M | -22.33M | -54.52M | -7.46M | -40.98M | -38.70M | -36.49M | -30.26M | 808.00K | -26.07M | -22.55M | -121.62M | -53.87M | -39.01M | -35.64M | -75.97M | -67.03M | -69.66M | -65.82M | -86.33M | -85.63M | 150.74M | -90.17M | -136.06M | -70.41M | -54.81M | - | -41.23M | -12.76M | 25.71M | 2.73M | -37.10M |
| Diluted EPS | -0.08 | -0.37 | -1.00 | -0.39 | -0.32 | -0.34 | -0.46 | -0.55 | -0.46 | -0.56 | -1.34 | -0.18 | -0.99 | - | - | - | 0.02 | -0.58 | -0.44 | - | -0.96 | -0.64 | -0.59 | -1.20 | -1.05 | -1.09 | -1.03 | -1.27 | -1.13 | 1.97 | -1.18 | -1.76 | -0.91 | -0.70 | - | -0.47 | -0.14 | 0.28 | 0.03 | -0.40 |
| R&D Expense | 14.67M | 17.68M | 18.41M | - | 20.86M | 19.48M | 19.61M | - | 24.64M | 34.46M | 32.45M | - | 33.44M | 37.93M | 33.22M | - | 30.25M | 30.79M | 32.35M | - | 47.95M | 51.81M | 48.41M | - | - | - | - | 7.50M | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 28.20M | 99.89M | 133.59M | 154.94M | 164.25M | 175.34M | 198.32M | - | 109.46M | 145.24M | 233.18M | 490.73M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 4.42M | 11.45M | 7.74M | 10.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 105.04M | 133.79M | 225.43M | 480.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 424.85M | 510.53M | 546.82M | 543.21M |
| Operating Income | - | - | -30.26M | -24.77M | -79.81M | -50.75M | -58.21M | -53.79M | -80.04M | -137.36M | -176.16M | - | -319.81M | -376.74M | -321.39M | -62.82M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -299.42M | -326.25M | -265.77M | 22.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 11.01M | 11.33M | 11.18M | 10.75M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -331.15M | -376.11M | -320.51M | -49.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 313.00K | 223.00K | 120.00K | 988.00K |
| Net Income | -23.02K | -14.82K | -30.34M | -34.62M | -110.94M | 117.24M | -47.90M | -59.73M | -102.68M | -146.43M | -169.43M | - | -278.48M | -111.40M | -321.55M | -25.55M |
| Diluted EPS | - | - | - | -2.44 | -4.43 | 3.17 | -1.29 | -1.54 | -2.54 | -3.46 | -3.56 | - | -4.37 | -1.50 | -4.08 | -0.29 |
| R&D Expense | - | - | 662.50K | 7.08M | 47.80M | 50.43M | 70.82M | 78.17M | 123.76M | 140.96M | - | - | 7.50M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2011 | Dec 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 19.57K | - | 2.39M | 20.50M | 135.47M | 512.26M | 525.28M | 520.35M | 709.16M | 604.80M | 607.44M | - | 672.59M | 788.91M | 594.12M | 605.19M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 486.44M | 616.77M | 416.70M | 437.56M |
| Cash & Equivalents | - | 10.05K | - | 11.00K | 6.00M | 18.20M | 37.80M | 41.00M | 99.39M | 102.87M | 62.44M | 84.77M | - | 61.69M | 58.18M | 58.53M | 93.03M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.52M | 9.41M | 6.20M | 5.88M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.65M | 21.18M | 27.12M | 80.13M |
| Total Liabilities | - | - | - | 5.80M | 40.17M | 172.72M | 212.29M | 217.51M | 227.21M | 390.91M | 383.60M | 396.23M | - | 629.73M | 588.10M | 535.05M | 490.36M |
| Current Liabilities | - | 555.86K | - | 5.80M | 36.56M | 107.54M | 86.98M | 83.26M | 85.67M | 104.62M | 95.45M | 92.66M | - | 142.16M | 177.91M | 200.75M | 159.90M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.55M | 377.26M | 310.31M | 311.72M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 407.49M | 404.78M | 401.58M | 328.73M |
| Total Equity | -60.26K | -536.28K | -63.08K | -3.41M | -19.67M | -37.25M | 299.97M | 307.77M | 293.13M | 318.25M | 221.20M | 211.21M | - | 42.85M | 200.81M | 59.08M | 114.83M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.29M | 75.37M | 87.45M | 90.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -689 | -49 | -2.74M | -17.59M | - | -1.39M | -3.44M | 7.40M | -24.96M | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M | -237.47M | 37.78M |
| Investing Cash Flow | - | - | -1.70M | -5.41M | - | -80.60M | 10.37M | 45.60M | -203.29M | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M | 99.33M | 27.89M |
| Financing Cash Flow | - | - | 4.44M | 28.98M | 95.32M | 101.60M | -3.85M | 5.45M | 231.86M | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M | 139.42M | -33.47M |
| Capital Expenditure | - | - | -24.77K | -117.00K | -663.00K | -22.00K | -1.43M | -887.00K | -727.00K | -195.00K | -6.77M | -5.10M | -191.00K | -668.00K | - | - |
| Free Cash Flow | - | - | -2.76M | -17.71M | - | -1.41M | -4.87M | 6.52M | -25.68M | -58.41M | -49.51M | -19.89M | -186.48M | -280.69M | - | - |
| Share Buybacks | - | - | - | 958.00K | 2.26M | 0 | 0 | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating Margin % | - | - | - | - | -283.0% | -50.8% | -43.6% | -34.7% | -48.7% | -78.3% | -88.8% | - | -292.2% | -259.4% | -137.8% | -12.8% |
| Net Margin % | - | - | - | - | -393.4% | 117.4% | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | - | -254.4% | -76.7% | -137.9% | -5.2% |
| ROE % | 38.2% | 23.5% | 890.4% | 176.1% | 297.8% | 39.1% | -15.6% | -20.4% | -32.3% | -66.2% | -80.2% | - | -649.9% | -55.5% | -544.3% | -22.2% |
| ROCE % | - | - | 887.9% | 154.2% | -285.7% | -11.9% | -13.2% | -12.4% | -13.2% | -27.0% | -34.2% | - | -60.3% | -61.7% | -81.7% | -14.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 12.28% | 11.42M | $662.34M |
| 2 | FMR, LLC | 11.79% | 10.97M | $636.14M |
| 3 | Blackrock Inc. | 8.38% | 7.79M | $451.94M |
| 4 | State Street Corporation | 5.33% | 4.96M | $287.68M |
| 5 | Armistice Capital, LLC | 5.27% | 4.90M | $284.05M |
| 6 | Perceptive Advisors Llc | 4.45% | 4.14M | $240.27M |
| 7 | Vanguard Capital Management LLC | 4.35% | 4.05M | $234.66M |
| 8 | Nomura Asset Management International Inc | 3.52% | 3.27M | $189.69M |
| 9 | Geode Capital Management, LLC | 2.55% | 2.37M | $137.43M |
| 10 | Renaissance Technologies, LLC | 2.11% | 1.97M | $114.07M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TVTX
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaEgyck9rUWYzOG8tSnd1aktJZzRCTnQ3LVN4N2hMdzNTSUpaSXk4Tk9rd01femR2VmpDZWZpWkhSTzdoLXJpQ0ROTjB4MXEwbWkwMHpoYVM0N3hSbzFvOUNPVk5SMS1ES1N1bkowRUc5ZFBpMkM5YVZCSDZaRWQ1ZWJLa3o0dVc0ZUcxeT…
New Travere hires receive 41,600-share stock and RSU package - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNbGlYdnN2NWVTR0ozSjVweTF6VzJraW12Vk5Gb3VPZHEwX2hvYUxldHhZNXV6MUFhLWdtY0IyMGF3U21nYVdRRDJSekVTQmVZYkxxZjUycWpONXctT0thUGtfOU9abHo2LTl3anVsWDRRd01tbXJHNzBqZTFRWHpQUGpuWkdzcU1TRGpDcG…
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxONzJOY0hzQ0QyMDFZcFpBSmk1NmVWcmg3NUNqNGdkWl9lZXRDcHM4X3FDNHlzbW9FM2w5OGt4OW0tUTJfSDRlVTBQZkVXZko4cXJ5X0NZbzV2dTdPbld5bE1DWDJrYVlFdlRxNXZNREFESkpuRjM3Q0tPNnl6WUJiTTY1dEtYYmxyNmZ4Mk…
Why (TVTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOb1A3LVJsYlNYMElQVnVDNWZmenZLRjgxT1IwQnF3M2V6czhrZVU2QXNsQXBJWXVyZ3pTc3NINUhkVUJRZFhKMzByclpCNjQ5OE8zYVNSX3RiVkttN3lzSVRhWU15M3dxNVhiOHlCcnFleVR4NGJXWnU5NFBERVA5RXpBejBSTUlyTUNZc0…
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOMmdTMW9lOU1FQ2VYNGhqU1JaclkwdzFwemZJS0ZFYlcyTG9Va2ltZDdBNnBVWE1ibmpnZXZtZUZVUFZGOVA3QlhNa0dJS2Q2ekJ5bUQ5WXJnSVlPREEwM2I3Uk11b1VtN1FRd2xkZFl5a3hSZEZ0bjM1cW94SDd5cTZzTm1PUQ?oc=5" t…
Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZVVBSVZKY3pieHE0QnljWTRFa1ViYXJsTFhxWkhTc0ZpRFo0cWN4QmpYQTdBcXdLclpUSFlON1ZRb3NVLURheUV5eGtWNFdZbGNKeVVYYzZsWXhaei1Lbnl5RC1OZnk2dUZ3VldHMmJ3Y3I5OHdNMUJoU1JtcVlqLTlHMTJSZTRUNUY1Tm…
TVTX — Frequently Asked Questions
What is the current share price of Travere Therapeutics, Inc. (TVTX)?
As of 2026-07-14 21:23 PDT, Travere Therapeutics, Inc. (TVTX) trades at $57.06 on NasdaqGM. Its 52-week range is $15.32 to $59.03.
What is the market capitalisation of TVTX?
Travere Therapeutics, Inc. (TVTX) has a market capitalisation of $5.31B on NasdaqGM.
What is the P/E ratio of TVTX?
TVTX trades at a trailing price-to-earnings (P/E) ratio of -114.12. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 48.73.
What is the return on equity (ROE) of TVTX?
TVTX has a return on equity (ROE) of -69.38%. Its return on capital employed (ROCE) is -8.65%.
Is TVTX a good stock to buy?
This page provides a data-driven analysis of Travere Therapeutics, Inc. (TVTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.